窑Nasopharyngeal Carcinoma Column窑 Nasopharyngeal carcinoma (NPC) is the most common headandneck malignancy in southern China. Platinums combined with 5fluorouracil (5FU) is the most frequently used chemotherapy for NPC patients 1,2 . However, the response rate has been maintained at 50% 60%. As an effective monotherapy for headandneck malignancies 3 , docetaxol is characterized by simple and shortterm administration. Chan . 4 reported that the 2year survival rate and diseasefree survival rate were 91.8% and 78.5%, respectivelyin patients with local advanced NPC who were treated by two cycles of inductive chemotherapy with docetaxol plus carboplatin (TC) and subsequent concurrent chemotherapy with cisplatin. In the hope of seeking for new schemes to improve the therapeutic efficacy for localadvanced NPC, we compared TC scheme and 5FU plus carboplatin (FC) scheme in treating NPC patients in terms of shortterm response rate, toxicity and side effects and tolerability.
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Inclusion criteria: patients aged between 18 and 60 years; no contraindications for chemotherapy; pathology confirmed differentiated or undifferentiated nonkeratinizing carcinoma (by WHO classification); the disease was clinically rated as stage III, IVa or IVb (by UICC staging system 2002); the patients were initial treated and without chemotherapy, surgery or radio therapy ; general condition was good, with a Karnofsky (KPS) score of 逸 80. adenocarcinoma; those aged > 60 or < 18 years; KPS score < 80; abnormal liver and kidney functions; heart disease or impaired heart function; those who had received surgery for primary or metastatic lesions and those who had received radiotherapy or chemotherapy.
Between November 1st, 2005 and December 1st, 2008, a total of 58 patients with mid or latestage NPC were randomly divided into testing group and control group as stratified by clinical staging and genders. The median age was 46 years in testing group and 43 years in control group. Clinical data were generally consistent between the two groups, with statistically insignificant difference ( > 0.05) ( Table 1 ).
Testing group (TC regimen) was given two cycles of inductive chemotherapy with docetaxol (70 mg/m 2 ) combined with carboplatin (AUC = 6), with three weeks in each cycle. After that, two cycles of carboplatin monotherapy (AUC = 6) were conducted as concurrent chemotherapy, with three weeks in each cycle. In control group (FC regimen), docetaxol was replaced by 5FU; treatment otherwise was the same as in testing group. Within three days before, during and within three days after docetaxol treatment, oral dexamethasone 7.5 mg was administered every 12 h to prevent possible sodium and fluid retention caused by docetaxol. Radiotherapy was given with cobalt60 ( 60 Co) or 6 MV or 8 MV photon beam by linear accelerator, at the dosage of 2.0 Gy/fraction and 5 fractions/week. Radiation dosage was 6078 Gy in the nasopharynx and curative dosage of 6070 Gy in cervical lymph nodes. Radiotherapy was completed within six to nine weeks. Comparisons of shortterm efficacy and adverse events after treatment were performed between the two groups using 字 2 test; KaplanMeier method was used for analyses on survival. All statistical processing was conducted by SPSS13.0 software. Difference was considered statistically significant when < 0.05.
Each group of patients was supposed to receive 116 cycles of chemotherapy in total, with two cycles of inductive chemotherapy and two cycles of concurrent chemotherapy for each patient. In testing group, a total of 95 cycles of chemotherapy were completed, including 57 cycles of inductive chemotherapy and 38 cycles of concurrent chemotherapy. In this group, 13 patients completed all the chemotherapy as planned. In control group, a total of 86 cycles of chemotherapy were completed, including 57 cycles of inductive chemotherapy and 29 cycles of concurrent chemotherapy. Eight patients completed all the chemotherapy as planned. Due to grade IV myelosuppression, one patient in testing group and one in control group completed just one cycle of inductive chemotherapy. The average number of chemotherapy cycles was 3.31 and 2.83 in testing group and control group, respectively, with statistically significant difference ( = 0.043).
Efficacy in primary nasopharyngeal lesion and metastatic lesions in cervical lymph nodes was evaluated for the two groups of patients at the end of inductive chemotherapy and at three months after overall treatment. No significant difference was found in terms of shortterm efficacy. At three months after treatment, one patient of testing group and one of control group had incomplete remission of nasopharyngeal lesion; one patient of testing group and two of control group had incomplete remission of regional lymph nodes. However, complete remission was seen for these lesions at six months after the treatment even without further intervention (Table 2) .
Survival analyses with KaplanMeier showed that the 1year survival rates were 96.2% and 100% in testing group and control group, respectively, with statistically insignificant difference ( = 0.317). During one year of followup, three patients of testing group and one patient of control group developed distant metastasis; among the patients of control group, no local recurrence was seen within one year of followup, but one patient in control group had nasopharyngeal recurrence.
The occurrence rates of grades IIIIV leukopenia were 55.2% and 20.7% in testing group and control group ( = 0.008), and those of grades IIIIV neutropenia were 72.4% and 37.9% , respectively ( = 0.005). In testing group, 15 (51.7% ) patients had grade IV neutropenia; median time to normal neutrophil level after supportive treatment with colony stimulating factor was 4.5 days (range, 29 days). The occurrence rate of thrombocytopenia was lower in testing group than in control group ( = 0.013), but no significant difference was seen for the occurrence rate of anemia between the two groups ( > 0.05). One patient each from testing group and control group gave up the second cycle of inductive chemotherapy due to grade IV myelosuppression and poor efficacy of supportive treatment (Table 3) .
Incidence of grades III alopecia in testing group was 100% . In this group, ten patients experienced grades III weight gain during treatment and three of them had gained more than 10% of body weight. In all these patients, the body weight restored to pretreatment level at the end of the treatment. After the inductive chemotherapy, one patient presented swollen lower extremities, which was relieved after diuretic treatment. Another patient presented allergic reactions including mild dyspnea and reddish eruption in upper extremities during inductive chemotherapy and was improved after infusion rate was reduced and antianaphylaxis was given. Digestive reactions, mostly grade II nausea and vomiting, were more prominent in control group than in testing group ( = 0.018). After the first cycle of inductive chemotherapy, one female patient experienced grade II diarrhea and two patients had grade II mucositis (Table 3) .
Comprehensive strategy including radiotherapy and chemotherapy is currently the golden standard of treatment for patients with locally advanced NPC, whereas platinumbased chemotherapy is the most frequently used scheme for NPC patients 1, 2 . The latest metaanalysis showed that radiotherapy combined with chemotherapy could increase the 5year survival rate by 4% 6% and reduce the risk for death by 18% in patients with locally advanced NPC; it was also found that concurrent chemotherapy provided maximal survival benefit while inductive chemotherapy was slightly better in reducing distant metastasis 5, 6 . As an emerging new type of agents in recent years, taxanes (taxol and docetaxol) provide excellent efficacy for various kinds of solid tumors 7 . A phase I/II clinical trial demonstrated that TPF scheme provided a significantly higher 3year survival rate than PF scheme in treating headandneck squamous cell carcinoma 8 . Hui . 9 reported that patients with locally advanced NPC who were treated by two c ycles of inductive chemotherapy with docetaxol plus cisplatin and then concurrent chemotherapy with cisplatin had a significantly higher 3year progressionfree survival rate than those who w ere only given concurrent chemotherapy (88.2% vs. 59.5% ), and the toxicity and side effects were tolerable. Carboplatin provides radiosensitization as much as cisplatin, but induces milder gastrointestinal reactions and hematological toxicity than cisplatin 1014 . Chitapanarux . 15 reported a phase III clinical trial, which showed that the total survival rate and diseasefree survival rate in patients with locally advanced NPC were not significantly different between carboplatin group and cisplatin group, but patients of carboplatin group had significantly less renal toxicity, leukopenia and anemia and better compliance than those of cisplatin group. Chan . 4 reported that the 2year survival rate and diseasefree survival rate were 91.8% and 78.5% , respectively, in patients with localadvanced NPC who were treated by two cycles of inductive chemotherapy with docetaxol plus carboplatin and subsequent concurrent chemotherapy with cisplatin.
In this study, we observed the shortterm efficacy and adverse events with inductive chemotherapy of docetaxol combined with platinums. The results revealed statistically insignificant differences when comparing the response rates in primary nasopharyngeal lesion and regional metastatic lymph nodes of inductive chemotherapy of docetaxol plus carboplatin to those of control group. Therefore, TC scheme could produce similar shortterm efficacy as FC scheme. But the followup duration was short. Whether or not the tested scheme could provide longterm survival benefit for the patients had to be seen in further followups.
The hematological toxicity in testing group was similar to that shown in previously published reports 1618 . The main toxicity was neutropenia. During inductive chemotherapy and concurrent chemotherapy, testing group had a higher incidence of grade III neutropenia; statistically significant difference was revealed as compared with control group. But it took just a few days to restore normal neutrophil level after treatment with granulocyte colony stimulating factor, so the chemotherapy would not be delayed or discontinued if supportive treatment was given in a timely manner. However, thrombocytopenia was more common in control group. Since supportive treatment strategies for thrombocytopenia were limited, it had become one of the reasons for treatment delay or discontinuation.
In terms of nonhematological toxicity, we found that, beside prominent alopecia, ten patients with TC scheme experienced weight gain, which was probably due to fluid retention. But the patients did not report significant discomfort, and their body weight returned to the normal level at the end of the treatment. Furthermore, chest Xray and abdominal B ultrasonic examination revealed no hydrothorax or ascites, and the weight gain had not caused any treatment delay for the patients. Testing group had less other nonhematological toxicity than control group; in particular, gastrointestinal reactions were markedly milder than those in control group.
Patients of testing group had completed more cycles of chemotherapy as scheduled than those in control group, suggesting that patients had better compliance and tolerance with TC regimen than with FC regimen. Moreover, since administration of docetaxol is convenient and takes a min imal amount of time, docetaxol plus carboplatin administration can be completed within just one day, thus reducing the hospitalization stay for the patients. In conclusion, TC scheme provides reliable shortterm efficacy and tolerable toxicity and side effects in treating local advanced NPC. It produces better compliance in the patients than FC scheme. But its longterm efficacy should be confirmed by further followup studies.
